NRIX — Nurix Therapeutics, Inc. stock price, charts and financials

QT77Nurix Therapeutics, Inc.

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
23.22
+0.01+0.04%
OverviewShort InterestFilings
NRIXQT77Nurix Therapeutics, Inc.·NASDAQ
23.22+0.04%
TA
Loading chart...
Signal & projected range
Insider selling clusterHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
RARE+0.44%$25.02VCEL+0.20%$46.05VERA+0.41%$32.23ANAB+0.56%$53.66CLDX-0.97%$37.69TARS+3.86%$61.32BCRX-1.89%$8.81PHVS-1.13%$32.25
Snapshot
Index-P/E-EPS (ttm)-3.45Insider Own1.99%Shs Outstand103.78MPerf Week-0.73%
Market Cap2.41BForward P/E-EPS next Y-2.00Insider Trans-7.58%Shs Float98.28MPerf Month-2.93%
Enterprise Value2.40BPEG0.25EPS next Q-0.66Inst Own-Short Float18.29%Perf Quarter38.98%
Income-318.92MP/S65.52EPS this Y20.42%Inst Trans-Short Ratio9.14Perf Half Y31.95%
Sales36.77MP/B6.40EPS next Y27.13%ROA-63.74%Short Interest17.98MPerf YTD22.35%
Book/sh-P/C-EPS next 5Y-ROE-76.09%52W High25.10 -7.49%Perf Year95.37%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-77.32%52W Low8.20 183.05%Perf 3Y146.65%
Dividend Est.-EV/EBITDA-Sales past 3/5Y29.14% 36.08%Gross Margin-165.51%Volatility4.81% 4.98%Perf 5Y-24.45%
Dividend TTM-EV/Sales65.26EPS Y/Y TTM-19.79%Oper. Margin-982.37%ATR (14)1.20Perf 10Y-
Dividend Ex-Date-Quick Ratio6.34Sales Y/Y TTM-Profit Margin-928.44%RSI (14)55.61Recom2.00
Dividend Gr. 3/5Y-Current Ratio6.34EPS Q/Q-55.77%SMA20-1.47%Beta1.74Target Price34.67
Payout0.00%Debt/Eq0.14Sales Q/Q-79.55%SMA5013.84%Rel Volume0.38Prev Close23.21
Employees317LT Debt/Eq0.10EarningsOct 08SMA20035.81%Avg Volume2.00MPrice23.22
IPO DateJul 24, 2020Option/ShortYes / YesEPS/Sales Surpr.-12.05% -40.85%Net Debt/EBITDA0.03Volume761,615Change0.04%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-28-26ReiteratedMorgan StanleyOverweight$36 → $38
Jul-22-26ReiteratedUBSBuy$23 → $31
Jul-13-26ReiteratedMizuhoOutperform$34
Jul-10-26ReiteratedStifel Nicolaus$34 → $40
Jul-10-26ReiteratedHC Wainwright & Co.Buy$32 → $34
Jul-10-26ReiteratedTruist SecuritiesBuy$32 → $34
Jul-10-26ReiteratedRBC CapitalOutperform$29 → $33
Jun-18-26ReiteratedRobert W. Baird$26 → $33
Jun-09-26ReiteratedUBSBuy$35 → $23
Jun-09-26ReiteratedBTIGBuy$30 → $32
Latest News
Jul-28-26
Jul-28-2601:00PM
Morgan Stanley Maintains Overweight on Nurix Therapeutics, Raises Price Target to $38Benzinga
Jul-23-26
Jul-23-2603:21PM
Roche H1 Sales Decline on Currency Headwinds, Key Drugs Keep Momentumzacks.com
Jul-21-26
Jul-21-2604:07PM
Nurix Therapeutics To Carry 40% Of Clinical Development Costs Of Bexobrutideg, Roche To Carry 60%Benzinga
04:01PM
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurologyglobenewswire.com
03:16AM
Amova Asset Management Americas Inc. Sells 109,408 Shares of Nurix Therapeutics, Inc. $NRIXdefenseworld.net
Jul-15-26
Jul-15-2601:10PM
RHHBY's Gazyva Gets FDA Priority Review for Label Expansionzacks.com
Jul-13-26
Jul-13-2608:21AM
Mizuho Maintains Outperform on Nurix Therapeutics, Raises Price Target to $34Benzinga
Jul-09-26
Jul-09-2606:26PM
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimateszacks.com
04:01PM
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com
Jul-01-26
Jul-01-2611:01AM
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Declinezacks.com
10:55AM
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Tradezacks.com
Jun-25-26
Jun-25-2601:05PM
12 Health Care Stocks Moving In Thursday's Intraday SessionBenzinga
Jun-18-26
Jun-18-2609:00AM
Baird Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33Benzinga
Jun-15-26
Jun-15-2608:16AM
Needham Reiterates Buy on Nurix Therapeutics, Maintains $34 Price TargetBenzinga
Jun-11-26
Jun-11-2609:48AM
Nurix Therapeutics Deal With Roche Is Worth Betting OnSeekingAlpha
Company

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
11/30/2025
FY 2024
11/30/2024
FY 2023
11/30/2023
FY 2022
11/30/2022
FY 2021
11/30/2021
FY 2020
11/30/2020
FY 2019
11/30/2019
FY 2018
11/30/2018
Total Revenue8455773930183137
Cost of Goods Sold Incl. D&A19222189184116664541
Gross Profit65-167-112-146-87-49-14-3
Selling, General and Administrative Excl. Other53464338311687
Research and Development308222189184116664541
Other Operating Expense-10-222-189-184-116-66-45-41
Operating Income-286-213-155-184-118-65-22-10
Interest Expense
00000000
Unusual Expense
————————
Non-Operating Income (Expense)22201141111
Net Income Before Taxes-264-193-144-180-117-64-21-9
Income Taxes10000-2101
Consolidated Net Income-264-194-144-180-117-43-22-9
Net Income From Continuing Operations-264-194-144-180-117-43-22-9
Net Income-264-194-144-180-117-43-22-9
EPS (Recurring)-3.05-2.88-2.65-3.71-2.73-2.76-0.56-0.59
EPS (Basic, Before Extraordinaries)-3.05-2.88-2.65-3.71-2.73-2.76-0.56-0.59
EPS (Diluted)-3.05-2.88-2.65-3.71-2.73-2.76-0.56-0.59
EBITDA-245-185-138-176-115-63-20-7
Other After Tax Adjustments
————————
Stock Option Compensation Expense
————————
Price To Earnings Ratio
————————
Price To Sales Ratio18.3126.934.3615.5741.3137.88——
Gross Margin77.38-303.64-145.45-374.36-290.00-272.22-45.16-8.11
Operating Margin-340.48-387.27-201.30-471.79-393.33-361.11-70.97-27.03
Net Margin-314.29-352.73-187.01-461.54-390.00-238.89-70.97-24.32
Shares Outstanding8767544943163916
Market Capitalization1,5381,4813366071,239682——
Operating Lease Expense
————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$27.16$21.81$16.47$11.12$5.77● Close Price0.00K205.91K411.82K617.73K823.64KUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
van Houte HansChief Financial OfficerJul 30 '26Sale23.382,84566,52444,927Jul 30
van Houte HansChief Financial OfficerJul 30 '26Option Exercise0.0010,180047,772Jul 30
Ring ChristineChief Legal OfficerJul 30 '26Option Exercise0.0010,180023,759Jul 30
Ring ChristineChief Legal OfficerJul 30 '26Sale23.383,84789,95419,912Jul 30
Hansen GwennChief Scientific OfficerJul 30 '26Option Exercise0.0010,1800125,185Jul 30
Hansen GwennChief Scientific OfficerJul 30 '26Sale23.383,84789,954121,338Jul 30
Ring ChristineChief Legal OfficerJul 02 '26Option Exercise5.4711,00860,17424,587Jul 02
Ring ChristineChief Legal OfficerJul 02 '26Sale23.5611,008259,36613,579Jul 02
Hansen GwennChief Scientific OfficerJun 25 '26Sale20.005,394107,880115,005Jun 25
Ring ChristineChief Legal OfficerJun 25 '26Option Exercise8.0528,935232,84742,514Jun 25
Ring ChristineChief Legal OfficerJun 25 '26Sale20.0628,935580,50613,579Jun 25
Ring ChristineChief Legal OfficerJun 02 '26Option Exercise1.863,4226,36521,727Jun 02
Ring ChristineChief Legal OfficerJun 02 '26Sale16.608,148135,25313,579Jun 02
van Houte HansChief Financial OfficerMay 05 '26Sale16.6014,055233,31937,592May 05
Ring ChristineChief Legal OfficerMay 04 '26Sale16.968,148138,21018,305May 04
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.